Abstract
Galectin-3 plays a role in tissue inflammation, repair, and fibrosis. This article specifically focuses on heart failure (HF), in which galectin-3 has been shown to be a useful biomarker in prognosis and risk stratification, especially in HF with preserved ejection fraction. Experimental research has shown that galectin-3 directly induces pathologic remodeling of the heart, and is therefore considered a culprit protein in the development of cardiac fibrosis in HF, with potentially relevant clinical implications. In summary, galectin-3 is a biomarker and biotarget in cardiac remodeling and fibrosis and future research will target galectin-3–centered diseases.
| Original language | English |
|---|---|
| Pages (from-to) | 75-92 |
| Number of pages | 18 |
| Journal | Heart Failure Clinics |
| Volume | 14 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2018 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2017 Elsevier Inc.